Antibodies pp 275-288 | Cite as

Regulatory and Legal Requirements for the Manufacture of Antibodies

  • Lincoln Tsang

Abstract

Monoclonal antibodies are antibodies which have a defined single amino sequence, specificity and affinity. They can be obtained from immortalised hybridoma or B lymphocytes or by recombinant DNA technology. The development of these techniques has paved the way for the design and production of specific monoclonal antibodies with the requisite antigenic determinants for the treatment and diagnosis of a range of clinical indications.

Keywords

Arthritis Albumin Europe Marketing Assure 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvarez R D, Curiel DT (1997) Human Gene Therapy 8:229–242PubMedCrossRefGoogle Scholar
  2. Committee for Proprietary Medicinal Products Guideline “Production and Quality Control of Monoclonal Antibodies” Eudra/B/94/014Google Scholar
  3. Committee for Proprietary Medicinal Products Guideline “Use of Transgenic Animals in the Manufacture of Biological Medicinal Products for Human Use” Eudra/B/93/17Google Scholar
  4. Committee for Proprietary Medicinal Products Note for Guidance on Plasma-Derived Medicinal Products (CPMP/BWP/269/95)Google Scholar
  5. Committee for Proprietary Medicinal Products Not for Guidance on Quality of biotechnological products: analysis of the expression construct in cells used for production of r-DNA-derived protein products (CPMP/ICH/139/95)Google Scholar
  6. Committee for Proprietary Medicinal Products (CPMP) Note for Guidance on Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals (ICH S6 CPMP/ICH/302/95)Google Scholar
  7. Committee for Proprietary Medicinal Products (CPMP) Note for Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (ICH Q6B CPMP/ICH/365/96)Google Scholar
  8. Committee for Proprietary Medicinal Products Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products (CPMP/BWP/3088/99)Google Scholar
  9. Committee for Proprietary Medicinal Products Note for Guidance on Development Pharmaceutics Annex: Development Pharmaceutics for Biotechnological and Biological Products (CPMP/BWP/328/99)Google Scholar
  10. Committee for Proprietary Medicinal Products Points to Consider on Quality Aspects of Medicinal Products Containing Active Substances Produced by Stable Transgene Expression in Higher Plants (CPMP/BWP/764/02)Google Scholar
  11. Committee for Proprietary Medicinal Products Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products (EMEA/410/01/2)Google Scholar
  12. Committee for Proprietary Medicinal Products Note for Guidance on the use of Bovine Serum in the manufacture of Human Biological Medicinal Products (CCPMP/BWP1793/02)Google Scholar
  13. Commission Directive 2003/63/EC OJ L159/46Google Scholar
  14. Commission Directive 91/356/EEC OJ L193/30Google Scholar
  15. Council Regulation (EEC) 2309/93 OJ L214/1Google Scholar
  16. Directive 2001/83/EC of the European Parliament and of the Council OJ L311/67Google Scholar
  17. European Commission: The Rules Governing Medicinal Products in the European Union Volume IV: Good Manufacturing Practice for Medicinal PracticeGoogle Scholar
  18. Food and Drug Administration Points to Consider in Human Somatic Cell Therapy and Gene Therapy (1991)Google Scholar
  19. Food and Drug Administration Points to Consider in the Manufacture and Testing of Therapeutic Products for Human Use Derived from Transgenic Animals (1993)Google Scholar
  20. Food and Drug Administration Guidance for Industry: Drags, Biologics and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals (2002)Google Scholar
  21. Hudson PJ, Souriau C (2003) Nature Medicine 9(1):129–134PubMedCrossRefGoogle Scholar
  22. Kohler G and Milstein C (1975) Nature 256:495–497PubMedCrossRefGoogle Scholar
  23. Pelegrin M, Marin M, Noel D, Peichaczyk M (1998) Human Gene Therapy 9:2165–2175PubMedCrossRefGoogle Scholar
  24. Tsang L, Knudsen LH, Theilade MD (2001 ) Regulatory Affairs Journal 13(4):275–278Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Lincoln Tsang
    • 1
  1. 1.Of Counsel, Arnold & PorterLondonEngland

Personalised recommendations